Too early to tell. This stock will probably trade 10X its normal volume in normal trading so pre-market shares are chump change and not to be used as a barometer. It is my opinion that the jury is still out. I mentioned elsewhere that there remains a hurdle and that is the basis for contention between RMTI and the FDA on trial design. We really have no information on this issue and how this discrepancy will affect the approval process.
I hate you people with no basis in medicine, spreading your BS to layman. The study was a "resounding success". Check my earlier 8 post special on the pathophysiology of the drug. Stop scaring longs, you will get burned today shortie.